Novo Nordisk’s blockbuster weight loss drug Wegovy has received approval from the Food and Drug Administration for a new use: reducing the risk of heart attacks, strokes, and cardiovascular-related death in overweight or obese adults with heart disease. The approval was based on a study showing a reduction in cardiovascular events among those taking the drug compared to a placebo.
The new indication for Wegovy could lead to broader insurance coverage and increased access for patients who qualify. However, cost considerations have led some employers and health plans to limit coverage of the medication. Drugmakers have also struggled to meet demand, with shortages of Wegovy reported.
The updated label for Wegovy may increase pressure on payers and employers to cover the medication, especially for older adults with heart disease who could benefit from it. Despite potential side effects such as muscle loss, the benefits of Wegovy may outweigh the risks for many patients.
With millions of people in the U.S. potentially eligible for Wegovy to prevent cardiovascular issues, the drug’s new approval highlights its potential beyond weight reduction. However, challenges remain in making the medication accessible to those who could benefit from it.
Source
Photo credit www.nytimes.com
